Gemcitabine
Phase 1/2Completed 0 watching 0 views this week⚡ Active
41
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Gastrointestinal Neoplasms
Conditions
Gastrointestinal Neoplasms, Ovarian Neoplasms
Trial Timeline
Oct 1, 2003 → May 1, 2011
NCT ID
NCT00390182About Gemcitabine
Gemcitabine is a phase 1/2 stage product being developed by Eli Lilly for Gastrointestinal Neoplasms. The current trial status is completed. This product is registered under clinical trial identifier NCT00390182. Target conditions include Gastrointestinal Neoplasms, Ovarian Neoplasms.
Hype Score Breakdown
Clinical
13
Activity
8
Company
10
Novelty
4
Community
3
Clinical Trials (7)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00337259 | Phase 2 | Terminated |
| NCT00191711 | Phase 2 | Completed |
| NCT00191971 | Phase 2 | Completed |
| NCT00390182 | Phase 1/2 | Completed |
| NCT00491114 | Phase 2 | Completed |
| NCT02046304 | Phase 1 | Completed |
| NCT00146276 | Phase 3 | UNKNOWN |
Competing Products
20 competing products in Gastrointestinal Neoplasms